Elicio Therapeutics to discuss success of Amphiphiles enabled T cell therapies at CAR-TCR Digital Summit Europe

On February 15, 2021 Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, reported Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer, will co-lead a workshop, "Improving Efficacy and Solid Tumor Infiltration with Combination Strategies," at the upcoming CAR-TCR Digital Summit Europe, February 16 – 18, 2021 (Press release, Elicio Therapeutics, FEB 15, 2021, View Source [SID1234575073]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, orchestrating the immune response, to significantly amplify and enhance the body’s own system of defenses to defeat cancer and stop its recurrence. When combined with CAR-T therapy, AMP-CAR-T amplifiersspecifically designed to bind to the CAR receptor are presented on the cell surface of immune cells in the lymph nodes. CAR-T cells passing through the lymph nodes en route to the tumor see these AMP-CAR-T amplifiers on the surface of specialized antigen presenting cells (APCs), which then deliver potent activating signals to T cells to coordinate their expansion, development of anti-tumor functions, and mobilization against tumors.

"Through published studies in mice, Amphiphile activation of the chimeric antigen receptor when CAR-T cells entered the native micro-environment of lymph nodes, enhanced treatment of multiple solid tumors," said Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer. "We have seen that this combination approach enhances trafficking, infiltration and persistence. Such potent amplification of the engineered T cell immune responses were critical, enabling prolonged survival and durable cures in solid tumor models where CAR-T alone had no effect."

At the summit Dr. Haqq will discuss:

Activation of CAR-T cells with Amphiphiles delivered to the lymph nodes to induce massive CAR-T expansion.
Lymph node activation to improve CAR-T function.
Ten-fold improvement in CAR-T trafficking into the solid tumors.
Durable complete responses observed for solid tumors across cancer types.
Persistence of CAR-T cells enabling rejection of additional cancer cells in rechallenge experiments that used doses lethal to untreated mice.
Induction of antigen spreading using the Amphiphile technology to recruit antitumor T cells to participate in a broad tumor attack.
Elicio is developing the AMP-CAR-T platform for combination with CAR-T cell therapies in a variety of settings including those targeting CD19, BCMA, and several solid tumor indications.